Last $125.55 USD
Change Today -1.84 / -1.44%
Volume 4.5M
As of 8:10 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

David L. Lacey M.D.

Supervisory Director, arGEN-X N.V
AgeTotal Calculated CompensationThis person is connected to 63 board members in 4 different organizations across 4 different industries.

See Board Relationships
61€37,000

Background*

Dr. David L. Lacey, M.D. served as Senior Vice President of Research at Amgen Inc. until July 2011. Dr. Lacey served as Senior Vice President and Head of Discovery Research at Amgen Inc. since May 22, 2007. Dr. Lacey served as Vice President of Research, and Amgen San Francisco Site Leader of Amgen Inc. He has over 30 years of basic and clinical research experience. Dr. Lacey joined Amgen in 1994 and served as Associate Medical Director, Department of Experimental Pathology ...

Read Full Background

Corporate Headquarters*

One Amgen Center Drive
Thousand Oaks, California 91320

United States

Phone: 805-447-1000
Fax: 805-447-1010

Board Members Memberships*

Director
2013-Present
Director

Education*

BS
University of Colorado–Boulder
MD
University of Colorado–Boulder

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation€37,000
Total Calculated Compensation€37,000
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $125.55 USD -1.84

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Gustav A. Christensen Chief Executive Officer, President and Director
Dyax Corp.
$615.6K
John W. Varian Chief Executive Officer, President and Director
XOMA Corporation
$489.3K
Michael S. O. Oredsson B.Int’l Bus Admin (Lund)Chief Executive Officer and President
BioInvent International AB
kr735.0K
John P. McLaughlin J.D.Chief Executive Officer, President, Director and Member of Litigation Committee
PDL BioPharma, Inc.
$1.2M
Jan G. J. van de Winkel Ph.D.Co-Founder, Chief Executive Officer and President
Genmab A/S
kr10.7M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.